Graphite Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Graphite Bio General Information

Description

Operator of a gene editing company designed to focus on the underlying causes of disease. The company discovers and develops cures for patients living with serious diseases.

Contact Information

Formerly Known As
Longbow Therapeutics Inc., Integral Medicines, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 611 Gateway Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Graphite Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 20-Mar-2024 Completed Generating Revenue
4. IPO 25-Jun-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 11-Mar-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Sep-2020 $45M $45M Completed Generating Revenue
1. University Spin-Out 01-Jun-2017 Completed Generating Revenue
To view Graphite Bio’s complete valuation and funding history, request access »

Graphite Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Graphite Bio’s complete cap table history, request access »

Graphite Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a gene editing company designed to focus on the underlying causes of disease. The company discovers and deve
Biotechnology
South San Francisco, CA
6 As of 2023

Berkeley, CA
 

Richmond, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Graphite Bio Competitors (9)

One of Graphite Bio’s 9 competitors is Caribou Biosciences, a Formerly VC-backed company based in Berkeley, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Caribou Biosciences Formerly VC-backed Berkeley, CA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Beam Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 9 competitors. Get the full list »

Graphite Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Graphite Bio Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Basecamp Fund Corporate Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
Cormorant Asset Management PE/Buyout Minority
Deerfield Management Venture Capital Minority
Federated Hermes (Pittsburgh) Asset Manager Minority
You’re viewing 5 of 17 investors. Get the full list »

Graphite Bio Acquisitions (1)

Graphite Bio’s most recent deal was a Reverse Merger with LENZ Therapeutics for . The deal was made on 21-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LENZ Therapeutics 21-Mar-2024 Reverse Merger Drug Discovery
To view Graphite Bio’s complete acquisitions history, request access »

Graphite Bio ESG

Risk Overview

Risk Rating

Updated January, 31, 2024

28.77 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,421

Rank

Percentile

Pharmaceuticals

Industry

of 928

Rank

Percentile

Biotechnology

Subindustry

of 407

Rank

Percentile

To view Graphite Bio’s complete esg history, request access »

Graphite Bio FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process